Answers are grounded in this paper and cite their sources.
• The study revealed significant structural diversity within the tyrosine kinase (TK) domain of hVEGFR1, with distinct regions associated with phosphorylase kinase and transferase activities. This finding enhances understanding of the functional versatility of the pivotal domain. • The identification of numerous potential phosphorylation sites across hVEGFR1, particularly within the TK domain, highlights its prospects as a hotspot for regulatory phosphorylation events. The known phosphorylation motifs were also confirmed, emphasizing the biological relevance of these sites. • The validation of a robust docking protocol for hVEGFR1-ligand interactions stands as a significantly task. This protocol's accomplishment in virtual screening led to the discovery of lead molecules and ATP analogs with high binding affinities for the TK domain, offering promising starting points for drug development. • The study provided a detailed view of the intricate binding forces between lead molecules and hVEGFR1. The identification of hydrogen bonds, electrostatic interactions, hydrophobic interactions, and π-sigma interactions deepened our understanding of the mechanisms governing hVEGFR1-ligand interactions. • Molecular dynamics simulations offered valuable insights into the stability of native and docked complexes. While the native complex remained stable, the docked complexes exhibited localized structural fluctuations, indicating potential allosteric effects and dynamic conformational changes induced by lead molecules. These findings are crucial for understanding the complex dynamics of hVEGFR1 and its interactions with potential inhibitors, with implications for drug design and development. Vascular Endothelial Growth Factor Receptor 1 (VEGFR1), is an enzyme with tyrosine kinase activity that plays a pivotal role in angiogenesis, the process of new blood vessel formation. This receptor is of significant clinical importance as it is implicated in various cancers, particularly non-small cell lung cancer (NSCLC), where its dysregulation leads to uncontrolled cell growth through ligand-induced phosphorylation. While commercially available drugs target VEGFR1, their prolonged use often leads to drug resistance and the emergence of mutations in cancer patients. To address these challenges, researchers have identified the human tyrosine kinase (hTK) domain of VEGFR1 as a potential therapeutic marker for lung malignancies. The 3D crystal structure of the hTK domain, obtained from Protein Data Bank (PDB ID: 3HNG), has provided vital structural insights of hVEGFR1. This study has revealed variations within the hVEGFR1 tyrosine kinase domain, distinguishing between regions associated with phosphorylase kinase and transferase activities. We identified numerous potential phosphorylation sites within the TK domain, shedding light on the protein's regulation and signaling possible. Detailed molecular interaction analyses have elucidated the binding forces between lead molecules and hVEGFR1, including hydrogen bonds, electrostatic, hydrophobic, and π-sigma interactions. The stability observed during molecular dynamics simulations further underscores the biological relevance of these interactions. Furthermore, docked complexes has highlighted localized structural fluctuations, offering insight into potential allosteric effects and dynamic conformational changes induced by lead molecules. These findings not only provide a comprehensive characterization of hVEGFR1 but also pave the way for the development of targeted therapies. Eventually, this study has the potential in identifying drug to combat diseases associated with hVEGFR1 dysregulation, including cancer and angiogenesis-related disorders, contributing to effective treatment strategies.
No takes yet. Share an insight, caveat, or question.
Munikumar et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: